Suicidal Ideation And Behavior clinical trials

Explore recruiting suicidal ideation and behavior clinical trials.

Recruiting suicidal ideation and behavior studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Suicidal Ideation And Behavior trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder (BALSAM-3)

Hungary, Romania, Poland, Sweden, Croatia, Spain +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder

Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

C5541010 - A PHASE 2A, RANDOMIZED, DOUBLE BLIND, SPONSOR OPEN, PLACEBO CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY OF PF 07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY

Hungary, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer's Disease

Italy, Portugal, Poland, France, Spain, Finland +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II/III, multicentre, 8-week run-in phase followed by a 12- week, prospective, parallel-group, double-blind, randomized withdrawal, placebo-controlled study, with a 52 week open label extension, to evaluate the efficacy and safety of daily 1.5 to 3.5 mg basimglurant in patients with pain associated with trigeminal neuralgia with suboptimal response to their current anti-pain therapy

Italy, Germany, Denmark, Poland, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious Distress

Bulgaria, Czechia, Germany, Poland, Hungary, Slovakia +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Suicidal Ideation And Behavior trials by city

Suicidal Ideation And Behavior in Toronto Suicidal Ideation And Behavior in Vancouver Suicidal Ideation And Behavior in Montreal Suicidal Ideation And Behavior in Calgary Suicidal Ideation And Behavior in Edmonton Suicidal Ideation And Behavior in Ottawa Suicidal Ideation And Behavior in Winnipeg Suicidal Ideation And Behavior in Quebec City Suicidal Ideation And Behavior in Hamilton Suicidal Ideation And Behavior in Kitchener Suicidal Ideation And Behavior in London Suicidal Ideation And Behavior in Halifax Suicidal Ideation And Behavior in New York Suicidal Ideation And Behavior in Los Angeles Suicidal Ideation And Behavior in Chicago Suicidal Ideation And Behavior in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease